D
Deutsche Biotech Innovativ AG
XETRA:DBI
Deutsche Biotech Innovativ AG
XETRA:DBI
Price:
27.4
EUR
Market Cap:
€26m
Relative Value
There is not enough data to reliably calculate the relative value of DBI.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
DBI
Relative Value
Base Case
Not Available
D
Multiples Across Competitors
DBI Competitors Multiples
Deutsche Biotech Innovativ AG Competitors
Deutsche Biotech Innovativ AG Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
D
|
Deutsche Biotech Innovativ AG
XETRA:DBI
|
26m EUR | 0 | -63.7 | -65 | -65 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
400.1B USD | 6.5 | 95.3 | 15.7 | 21.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
200.8B USD | 5.4 | 25.9 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
181.2B USD | 6.1 | 21 | 13.1 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
125.1B USD | 10.2 | 30.9 | 23.3 | 24.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.1B USD | 5.6 | 17.8 | 13.2 | 15.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.2B AUD | 3.1 | 34.6 | 11.4 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
38.3B EUR | 10.7 | 34.4 | 37.3 | 38.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
